Thursday, 11 February 2021 04:25

New studies show these two common drugs work against Covid-19

Rate this item
(0 votes)

A commonly used asthma treatment appears to reduce the need for hospitalizations and recovery time for Covid-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford have found. The 28-day study of 146 patients found the inhaled steroid, budesonide, reduced the risk of urgent care, emergency room visits or hospitalization by 90% when compared with usual care. Patients treated at home with budesonide also had a quicker resolution of fever and fewer persistent symptoms. In a report posted on Monday on medRxiv ahead of peer review, the researchers said they undertook the trial because they noticed that patients with chronic respiratory diseases like asthma, who are often prescribed inhaled steroids such as budesonide, were not needing to be hospitalized for Covid-19 as often as expected. "I am heartened that a relatively safe, widely available and well studied medicine ... could have an impact on the pressures we are experiencing during the pandemic," said study leader Mona Bafadhel.

Experimental drug may speed viral clearance

An experimental antiviral drug significantly sped up the time it took to "clear" the virus in Covid-19 patients who did not need to be hospitalized, Toronto researchers have found. In a small trial, patients who received a single injection of peginterferon-lambda were more than four times as likely to test negative for the virus within seven days as patients who received a placebo. "The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads" the authors reported on Friday in The Lancet Respiratory Medicine. "The magnitude of the viral load decline compared with that of placebo was much greater ... than has been reported with monoclonal antibody therapies," they added. "This treatment has large therapeutic potential," study leader Jordan Feld of Toronto Center for Liver Disease said in a statement. Respiratory symptoms also appeared to resolve faster with peginterferon-lambda therapy, but the trial was too small to demonstrate a statistically significant difference. Feld's team is planning a much larger trial, and studies are already underway testing the treatment in hospitalized patients.

 

Reuters

November 22, 2024

All good leaders have this mindset, no matter their background

David G. Ewing In today’s tech-driven business world, the ability to navigate technological challenges isn’t…
November 22, 2024

Tinubu’s borrowing spree retuning Nigeria back into debt peonage - Atiku

Former Vice President Atiku Abubakar has criticized the President Bola Tinubu-led administration for the increasing…
November 18, 2024

The magic and the minefield of confidence: Self doubt, hubris and everything in between - The Economist

Confidence is contagious. Someone declaring a position with ringing certainty is more likely to inspire…
November 16, 2024

Influencer eats pig feed in extreme attempt to save money

Popular Douyin streamer Kong Yufeng recently sparked controversy in China by eating pig feed on…
November 22, 2024

FG excited as pro-Biafra agitator Simon Ekpa arrested in Finland on terrorism charges

Simon Ekpa, the controversial leader of the pro-Biafra faction Autopilot, was arrested by Finnish authorities…
November 22, 2024

Here’s the latest as Israel-Hamas war enters Day 413

ICC issues arrest warrants for Israel's Netanyahu, Gallant and Hamas leader The International Criminal Court…
November 21, 2024

Nigeria comes top in instant payment system inclusivity index in Africa

Nigeria’s instant payment system is projected to advance to the maturity inclusion spectrum ahead of…
October 27, 2024

Nigeria awarded 3-0 win over Libya after airport fiasco

Nigeria have been awarded a 3-0 victory over Libya, and three vital points, from their…

NEWSSCROLL TEAM: 'Sina Kawonise: Publisher/Editor-in-Chief; Prof Wale Are Olaitan: Editorial Consultant; Femi Kawonise: Head, Production & Administration; Afolabi Ajibola: IT Manager;
Contact Us: [email protected] Tel/WhatsApp: +234 811 395 4049

Copyright © 2015 - 2024 NewsScroll. All rights reserved.